Associations - Orpathys (savolitinib)

MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	savolitinib Sensitive: A1 - Approval savolitinib Sensitive : A1	savolitinib Sensitive: A1 - Approval savolitinib Sensitive : A1
MET amplification	Renal Cell Carcinoma	MET amplification	Renal Cell Carcinoma	savolitinib Sensitive: A2 - Guideline savolitinib Sensitive : A2	savolitinib Sensitive: A2 - Guideline savolitinib Sensitive : A2
MET mutation	Renal Cell Carcinoma	MET mutation	Renal Cell Carcinoma	savolitinib Sensitive: B - Late Trials savolitinib Sensitive : B	savolitinib Sensitive: B - Late Trials savolitinib Sensitive : B
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	savolitinib Sensitive: C1 - Off-label savolitinib Sensitive : C1	savolitinib Sensitive: C1 - Off-label savolitinib Sensitive : C1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2
MET amplification	Gastric Cancer	MET amplification	Gastric Cancer	savolitinib Sensitive: C2 – Inclusion Criteria savolitinib Sensitive : C2	savolitinib Sensitive: C2 – Inclusion Criteria savolitinib Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	savolitinib Sensitive: C2 – Inclusion Criteria savolitinib Sensitive : C2	savolitinib Sensitive: C2 – Inclusion Criteria savolitinib Sensitive : C2
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib + savolitinib Sensitive: C3 – Early Trials gefitinib + savolitinib Sensitive : C3	gefitinib + savolitinib Sensitive: C3 – Early Trials gefitinib + savolitinib Sensitive : C3
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	gefitinib + savolitinib Sensitive: C3 – Early Trials gefitinib + savolitinib Sensitive : C3	gefitinib + savolitinib Sensitive: C3 – Early Trials gefitinib + savolitinib Sensitive : C3
MET overexpression	Gastric Cancer	MET overexpression	Gastric Cancer	savolitinib Sensitive: C3 – Early Trials savolitinib Sensitive : C3	savolitinib Sensitive: C3 – Early Trials savolitinib Sensitive : C3
EGFR mutation + MET mutation	Non Small Cell Lung Cancer	EGFR mutation + MET mutation	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3
MET overexpression + EGFR mutation	Non Small Cell Lung Cancer	MET overexpression + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3
EGFR mutation + MET overexpression + MET amplification	Non Small Cell Lung Cancer	EGFR mutation + MET overexpression + MET amplification	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3
MET mutation	Renal Cell Carcinoma	MET mutation	Renal Cell Carcinoma	durvalumab + savolitinib Sensitive: C3 – Early Trials durvalumab + savolitinib Sensitive : C3	durvalumab + savolitinib Sensitive: C3 – Early Trials durvalumab + savolitinib Sensitive : C3
EGFR exon 19 deletion + MET Amplification + MET D1228V	Lung Adenocarcinoma	EGFR exon 19 deletion + MET Amplification + MET D1228V	Lung Adenocarcinoma	osimertinib + savolitinib Resistant: C4 – Case Studies osimertinib + savolitinib Resistant : C4	osimertinib + savolitinib Resistant: C4 – Case Studies osimertinib + savolitinib Resistant : C4
EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y + MET Y1230C	Lung Adenocarcinoma	EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y + MET Y1230C	Lung Adenocarcinoma	osimertinib + savolitinib Resistant: C4 – Case Studies osimertinib + savolitinib Resistant : C4	osimertinib + savolitinib Resistant: C4 – Case Studies osimertinib + savolitinib Resistant : C4
MET D1228V	Non Small Cell Lung Cancer	MET D1228V	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C4 – Case Studies osimertinib + savolitinib Sensitive : C4	osimertinib + savolitinib Sensitive: C4 – Case Studies osimertinib + savolitinib Sensitive : C4
MET amplification + MET Exon 14 mutation	Lung Adenocarcinoma	MET amplification + MET Exon 14 mutation	Lung Adenocarcinoma	savolitinib Sensitive: C4 – Case Studies savolitinib Sensitive : C4	savolitinib Sensitive: C4 – Case Studies savolitinib Sensitive : C4
EGFR exon 19 deletion + MET amplification	Lung Adenocarcinoma	EGFR exon 19 deletion + MET amplification	Lung Adenocarcinoma	osimertinib + savolitinib Sensitive: C4 – Case Studies osimertinib + savolitinib Sensitive : C4	osimertinib + savolitinib Sensitive: C4 – Case Studies osimertinib + savolitinib Sensitive : C4
EGFR L858R + MET amplification	Lung Adenocarcinoma	EGFR L858R + MET amplification	Lung Adenocarcinoma	savolitinib Sensitive: C4 – Case Studies savolitinib Sensitive : C4	savolitinib Sensitive: C4 – Case Studies savolitinib Sensitive : C4
MET overexpression + HER-2 overexpression	Gastric Cancer	MET overexpression + HER-2 overexpression	Gastric Cancer	trastuzumab + savolitinib Sensitive: D – Preclinical trastuzumab + savolitinib Sensitive : D	trastuzumab + savolitinib Sensitive: D – Preclinical trastuzumab + savolitinib Sensitive : D
MET expression + HER-2 expression	Gastric Cancer	MET expression + HER-2 expression	Gastric Cancer	trastuzumab + savolitinib Sensitive: D – Preclinical trastuzumab + savolitinib Sensitive : D	trastuzumab + savolitinib Sensitive: D – Preclinical trastuzumab + savolitinib Sensitive : D
MET amplification	Gastroesophageal Cancer	MET amplification	Gastroesophageal Cancer	savolitinib + capmatinib Sensitive: D – Preclinical savolitinib + capmatinib Sensitive : D	savolitinib + capmatinib Sensitive: D – Preclinical savolitinib + capmatinib Sensitive : D
EGFR mutation + PTEN deletion	Non Small Cell Lung Cancer	EGFR mutation + PTEN deletion	Non Small Cell Lung Cancer	osimertinib + savolitinib + REGN5093-M114 Sensitive: D – Preclinical osimertinib + savolitinib + REGN5093-M114 Sensitive : D	osimertinib + savolitinib + REGN5093-M114 Sensitive: D – Preclinical osimertinib + savolitinib + REGN5093-M114 Sensitive : D
MET Y1230C	Non Small Cell Lung Cancer	MET Y1230C	Non Small Cell Lung Cancer	osimertinib + savolitinib + REGN5093-M114 Sensitive: D – Preclinical osimertinib + savolitinib + REGN5093-M114 Sensitive : D	osimertinib + savolitinib + REGN5093-M114 Sensitive: D – Preclinical osimertinib + savolitinib + REGN5093-M114 Sensitive : D

Orpathys (savolitinib)

Associations
(29)

Associations
(29)

Orpathys (savolitinib)

Associations(29)

Associations(29)

Associations
(29)

Associations
(29)